Limits...
The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.

Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y, Ma H - PLoS ONE (2015)

Bottom Line: The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated.A total of 6 studies were included for this meta-analysis.For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou province, China.

ABSTRACT

Background: Recent studies have shown that miR-155 play a positive role in the development of carcinoma. This meta-analysis aimed to identify the role of miR-155 in the survival of non-small cell lung cancer patients.

Methodology: Eligible studies were identified through database searches. Relevant data were extracted from each eligible study to assess the correlation between miR-155 expression and survival in lung carcinoma patients. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated. A total of 6 studies were included for this meta-analysis. For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant. Additionally, in Asian and America subgroups, greater expression levels of miR-155 were related to poor prognoses for lung cancer (HR 1.71 95% CI: 1.22-2.40, P = 0.002, HR 2.35 95% CI: 1.42-3.89 P = 0.001), while no significant relationship was present in a Europe subgroup (HR 0.75 95%CI: 0.27-2.10, P = 0.587).

Conclusions: These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America.

No MeSH data available.


Related in: MedlinePlus

Forrest plots of the studies that evaluated the hazard ratios of high miR-155 expression vs. low expression.(A) Forrest plots of the included studies that evaluated the hazard ratios of high miR-155 expression vs. low expression. HR (95% CI) with adenocarcinoma, squamous cell carcinoma (Tom Donnem) and in Maryland, Norway, Japan (Motonobu Saito) in turn. (B) Forrest plots of the survival data reported as cancer-specific survival (CSS). (C) Forrest plots of the survival data reported as overall survival (OS). (D) Forrest plots of the survival data reported as disease-free survival (DFS) and relapse-free survival (RFS). (E) Forrest plots of the survival data from Asia. (F) Forrest plots of the survival data from the Americas. (G) Forrest plots of the survival data from Europe.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556438&req=5

pone.0136889.g003: Forrest plots of the studies that evaluated the hazard ratios of high miR-155 expression vs. low expression.(A) Forrest plots of the included studies that evaluated the hazard ratios of high miR-155 expression vs. low expression. HR (95% CI) with adenocarcinoma, squamous cell carcinoma (Tom Donnem) and in Maryland, Norway, Japan (Motonobu Saito) in turn. (B) Forrest plots of the survival data reported as cancer-specific survival (CSS). (C) Forrest plots of the survival data reported as overall survival (OS). (D) Forrest plots of the survival data reported as disease-free survival (DFS) and relapse-free survival (RFS). (E) Forrest plots of the survival data from Asia. (F) Forrest plots of the survival data from the Americas. (G) Forrest plots of the survival data from Europe.

Mentions: In the included articles, a close relationship between miR-155 and lung cancer prognosis was reported. However, the HRs and 95% CIs were not given explicitly in one study [21]. The HR and 95% confidence intervals extracted from the included studies were combined, and the combined results revealed that high levels of expression of miR-155 may not be related to lung cancer prognosis. After the combination of the data, a high level of large heterogeneity was observed (I-squared = 78.3% p = 0.000); thus, a random effects model was selected (Fig 3A). The combined HR (95% confidence interval) was 1.30 (0.87, 1.95) (P = 0.207).


The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.

Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y, Ma H - PLoS ONE (2015)

Forrest plots of the studies that evaluated the hazard ratios of high miR-155 expression vs. low expression.(A) Forrest plots of the included studies that evaluated the hazard ratios of high miR-155 expression vs. low expression. HR (95% CI) with adenocarcinoma, squamous cell carcinoma (Tom Donnem) and in Maryland, Norway, Japan (Motonobu Saito) in turn. (B) Forrest plots of the survival data reported as cancer-specific survival (CSS). (C) Forrest plots of the survival data reported as overall survival (OS). (D) Forrest plots of the survival data reported as disease-free survival (DFS) and relapse-free survival (RFS). (E) Forrest plots of the survival data from Asia. (F) Forrest plots of the survival data from the Americas. (G) Forrest plots of the survival data from Europe.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556438&req=5

pone.0136889.g003: Forrest plots of the studies that evaluated the hazard ratios of high miR-155 expression vs. low expression.(A) Forrest plots of the included studies that evaluated the hazard ratios of high miR-155 expression vs. low expression. HR (95% CI) with adenocarcinoma, squamous cell carcinoma (Tom Donnem) and in Maryland, Norway, Japan (Motonobu Saito) in turn. (B) Forrest plots of the survival data reported as cancer-specific survival (CSS). (C) Forrest plots of the survival data reported as overall survival (OS). (D) Forrest plots of the survival data reported as disease-free survival (DFS) and relapse-free survival (RFS). (E) Forrest plots of the survival data from Asia. (F) Forrest plots of the survival data from the Americas. (G) Forrest plots of the survival data from Europe.
Mentions: In the included articles, a close relationship between miR-155 and lung cancer prognosis was reported. However, the HRs and 95% CIs were not given explicitly in one study [21]. The HR and 95% confidence intervals extracted from the included studies were combined, and the combined results revealed that high levels of expression of miR-155 may not be related to lung cancer prognosis. After the combination of the data, a high level of large heterogeneity was observed (I-squared = 78.3% p = 0.000); thus, a random effects model was selected (Fig 3A). The combined HR (95% confidence interval) was 1.30 (0.87, 1.95) (P = 0.207).

Bottom Line: The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated.A total of 6 studies were included for this meta-analysis.For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou province, China.

ABSTRACT

Background: Recent studies have shown that miR-155 play a positive role in the development of carcinoma. This meta-analysis aimed to identify the role of miR-155 in the survival of non-small cell lung cancer patients.

Methodology: Eligible studies were identified through database searches. Relevant data were extracted from each eligible study to assess the correlation between miR-155 expression and survival in lung carcinoma patients. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated. A total of 6 studies were included for this meta-analysis. For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant. Additionally, in Asian and America subgroups, greater expression levels of miR-155 were related to poor prognoses for lung cancer (HR 1.71 95% CI: 1.22-2.40, P = 0.002, HR 2.35 95% CI: 1.42-3.89 P = 0.001), while no significant relationship was present in a Europe subgroup (HR 0.75 95%CI: 0.27-2.10, P = 0.587).

Conclusions: These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America.

No MeSH data available.


Related in: MedlinePlus